Iovance Biotherapeutics, Inc. (IOVA)
IOVA Stock Price Chart
Explore Iovance Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze IOVA price movements and trends.
IOVA Company Profile
Discover essential business fundamentals and corporate details for Iovance Biotherapeutics, Inc. (IOVA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Oct 2010
Employees
838.00
Website
https://www.iovance.comCEO
Frederick G. Vogt
Description
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
IOVA Financial Timeline
Browse a chronological timeline of Iovance Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.17, while revenue estimate is $87.67m.
Earnings released on 7 May 2026
EPS came in at -$0.19 matching the estimated -$0.19, while revenue for the quarter reached $71.43m , missing expectations by -8.23%.
Earnings released on 24 Feb 2026
EPS came in at -$0.18 surpassing the estimated -$0.22 by +18.18%, while revenue for the quarter reached $86.71m , beating expectations by +7.44%.
Earnings released on 6 Nov 2025
EPS came in at -$0.25 surpassing the estimated -$0.29 by +13.79%, while revenue for the quarter reached $67.46m , missing expectations by -17.91%.
Earnings released on 7 Aug 2025
EPS came in at -$0.33 falling short of the estimated -$0.29 by -13.79%, while revenue for the quarter reached $59.95m , missing expectations by -23.45%.
Earnings released on 8 May 2025
EPS came in at -$0.36 falling short of the estimated -$0.25 by -44.00%, while revenue for the quarter reached $49.32m , missing expectations by -40.12%.
Earnings released on 27 Feb 2025
EPS came in at -$0.26 matching the estimated -$0.26, while revenue for the quarter reached $73.69m , beating expectations by +2.11%.
Earnings released on 7 Nov 2024
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $58.55m , missing expectations by -18.19%.
Earnings released on 8 Aug 2024
EPS came in at -$0.34 surpassing the estimated -$0.37 by +8.11%, while revenue for the quarter reached $31.11m , beating expectations by +26.50%.
Earnings released on 9 May 2024
EPS came in at -$0.42 surpassing the estimated -$0.45 by +6.67%, while revenue for the quarter reached $715.00k , missing expectations by -65.46%.
Earnings released on 28 Feb 2024
EPS came in at -$0.45 falling short of the estimated -$0.44 by -2.27%, while revenue for the quarter reached $482.00k , missing expectations by -65.32%.
Earnings released on 7 Nov 2023
EPS came in at -$0.46 matching the estimated -$0.46, while revenue for the quarter reached $469.00k , missing expectations by -72.73%.
Earnings released on 8 Aug 2023
EPS came in at -$0.47 surpassing the estimated -$0.81 by +41.98%, while revenue for the quarter reached $238.00k , missing expectations by -93.35%.
Earnings released on 9 May 2023
EPS came in at -$0.50 surpassing the estimated -$0.84 by +40.48%.
Earnings released on 28 Feb 2023
EPS came in at -$0.64 matching the estimated -$0.64.
Earnings released on 3 Nov 2022
EPS came in at -$0.63 surpassing the estimated -$0.64 by +1.56%.
Earnings released on 4 Aug 2022
EPS came in at -$0.63 falling short of the estimated -$0.60 by -5.00%.
Earnings released on 5 May 2022
EPS came in at -$0.58 surpassing the estimated -$0.64 by +9.38%.
Earnings released on 24 Feb 2022
EPS came in at -$0.63 falling short of the estimated -$0.56 by -12.50%.
Earnings released on 4 Nov 2021
EPS came in at -$0.55 falling short of the estimated -$0.52 by -5.77%.
Earnings released on 5 Aug 2021
EPS came in at -$0.53 falling short of the estimated -$0.52 by -1.92%.
IOVA Stock Performance
Access detailed IOVA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
